These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8435985)

  • 1. Association of erythrocyte aldose reductase activity with diabetic complications in type 1 diabetes mellitus.
    Hamada Y; Kitoh R; Raskin P
    Diabet Med; 1993; 10(1):33-8. PubMed ID: 8435985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients.
    Hamada Y; Hammon K; Raskin P
    J Diabetes Complications; 1992; 6(2):111-5. PubMed ID: 1611134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophil aldose reductase activity as a potential marker for neuropathy and cataract in diabetes.
    Dent MT; Veves A; Tebbs SE; Gonzalez AM; Malik RA; Boulton AJ; Ward JD; Wilson RM
    Diabet Med; 1991 Dec; 8(10):911-6. PubMed ID: 1838041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased erythrocyte aldose reductase activity in type 1 diabetic patients.
    Hamada Y; Kito R; Raskin P
    Diabet Med; 1991 Apr; 8(3):226-31. PubMed ID: 1828737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
    Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
    Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
    [No Abstract]   [Full Text] [Related]  

  • 6. High levels of erythrocyte aldose reductase and diabetic retinopathy in NIDDM patients.
    Nishimura C; Saito T; Ito T; Omori Y; Tanimoto T
    Diabetologia; 1994 Mar; 37(3):328-30. PubMed ID: 8174849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of diabetic neuropathy with Na/K ATPase gene polymorphism.
    Vague P; Dufayet D; Coste T; Moriscot C; Jannot MF; Raccah D
    Diabetologia; 1997 May; 40(5):506-11. PubMed ID: 9165217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between erythrocyte aldose reductase activity and the width of skeletal-muscle capillary basement membrane in insulin-dependent diabetes mellitus.
    Hamada Y; Hammon K; Raskin P
    J Diabetes Complications; 1992; 6(4):242-6. PubMed ID: 1482782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrocyte aldose reductase protein: a clue to elucidate risk factors for diabetic neuropathies independent of glycemic control.
    Takahashi Y; Tachikawa T; Ito T; Takayama S; Omori Y; Iwamoto Y
    Diabetes Res Clin Pract; 1998 Nov; 42(2):101-7. PubMed ID: 9886746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy.
    Reddy GB; Satyanarayana A; Balakrishna N; Ayyagari R; Padma M; Viswanath K; Petrash JM
    Mol Vis; 2008 Mar; 14():593-601. PubMed ID: 18385795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The level of erythrocyte aldose reductase is associated with the severity of diabetic retinopathy.
    Nishimura C; Hotta Y; Gui T; Seko A; Fujimaki T; Ishikawa T; Hayakawa M; Kanai A; Saito T
    Diabetes Res Clin Pract; 1997 Sep; 37(3):173-7. PubMed ID: 9306038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of aldose reductase in peripheral mononuclear cells from type 2 diabetic patients with microangiopathy.
    Hasegawa G; Obayashi H; Kitamura A; Hashimoto M; Shigeta H; Nakamura N; Kondo M; Nishimura CY
    Diabetes Res Clin Pract; 1999 Aug; 45(1):9-14. PubMed ID: 10499880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy?
    Ito T; Nishimura C; Takahashi Y; Saito T; Omori Y
    Diabetes Res Clin Pract; 1997 Jun; 36(3):161-7. PubMed ID: 9237782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacology of aldose reductase inhibitors.
    Kador PF; Robison WG; Kinoshita JH
    Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of diabetic autonomic neuropathy with red blood cell aldose reductase activity.
    Gupta P; Verma N; Bhattacharya S; Mahdi AA; Usman K; Tiwari S; Bhardwaj K
    Can J Diabetes; 2014 Feb; 38(1):22-5. PubMed ID: 24485209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil aldose reductase activity and its association with established diabetic microvascular complications.
    Dent MT; Tebbs SE; Gonzalez AM; Ward JD; Wilson RM
    Diabet Med; 1991 Jun; 8(5):439-42. PubMed ID: 1830528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aldose reductase in the development of diabetic complications.
    Kador PF
    Med Res Rev; 1988; 8(3):325-52. PubMed ID: 3136278
    [No Abstract]   [Full Text] [Related]  

  • 19. Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.
    Oishi N; Kubo E; Takamura Y; Maekawa K; Tanimoto T; Akagi Y
    Br J Ophthalmol; 2002 Dec; 86(12):1363-6. PubMed ID: 12446366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial role of aldose reductase activity and plasma glucose level in sorbitol accumulation in erythrocytes from diabetic patients.
    Hamada Y; Kitoh R; Raskin P
    Diabetes; 1991 Oct; 40(10):1233-40. PubMed ID: 1936586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.